Logo image of RXRX

RECURSION PHARMACEUTICALS-A (RXRX) Stock Fundamental Analysis

NASDAQ:RXRX - Nasdaq - US75629V1044 - Common Stock - Currency: USD

8.34  +0.68 (+8.88%)

Premarket: 8.04 -0.3 (-3.6%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to RXRX. RXRX was compared to 572 industry peers in the Biotechnology industry. The financial health of RXRX is average, but there are quite some concerns on its profitability. RXRX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RXRX has reported negative net income.
RXRX had a negative operating cash flow in the past year.
RXRX had negative earnings in each of the past 5 years.
RXRX had a negative operating cash flow in each of the past 5 years.
RXRX Yearly Net Income VS EBIT VS OCF VS FCFRXRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -100M -200M -300M

1.2 Ratios

RXRX has a Return On Assets (-52.00%) which is in line with its industry peers.
With a Return On Equity value of -72.01%, RXRX perfoms like the industry average, outperforming 54.87% of the companies in the same industry.
Industry RankSector Rank
ROA -52%
ROE -72.01%
ROIC N/A
ROA(3y)-38.3%
ROA(5y)-41.01%
ROE(3y)-51.48%
ROE(5y)-54.19%
ROIC(3y)N/A
ROIC(5y)N/A
RXRX Yearly ROA, ROE, ROICRXRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

The Gross Margin of RXRX (35.07%) is better than 75.75% of its industry peers.
The Profit Margin and Operating Margin are not available for RXRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 35.07%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RXRX Yearly Profit, Operating, Gross MarginsRXRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -500 -1K -1.5K -2K -2.5K

More info and screens

4

2. Health

2.1 Basic Checks

RXRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
RXRX has more shares outstanding than it did 1 year ago.
RXRX has a worse debt/assets ratio than last year.
RXRX Yearly Shares OutstandingRXRX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 50M 100M 150M 200M
RXRX Yearly Total Debt VS Total AssetsRXRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

RXRX has an Altman-Z score of 6.18. This indicates that RXRX is financially healthy and has little risk of bankruptcy at the moment.
RXRX has a Altman-Z score of 6.18. This is amongst the best in the industry. RXRX outperforms 81.77% of its industry peers.
RXRX has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.04, RXRX is doing worse than 60.88% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z 6.18
ROIC/WACCN/A
WACC9.44%
RXRX Yearly LT Debt VS Equity VS FCFRXRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 4.35 indicates that RXRX has no problem at all paying its short term obligations.
RXRX has a Current ratio (4.35) which is in line with its industry peers.
A Quick Ratio of 4.35 indicates that RXRX has no problem at all paying its short term obligations.
RXRX has a Quick ratio of 4.35. This is comparable to the rest of the industry: RXRX outperforms 51.15% of its industry peers.
Industry RankSector Rank
Current Ratio 4.35
Quick Ratio 4.35
RXRX Yearly Current Assets VS Current LiabilitesRXRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for RXRX have decreased by -6.16% in the last year.
The Revenue has grown by 37.64% in the past year. This is a very strong growth!
RXRX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 124.11% yearly.
EPS 1Y (TTM)-6.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.93%
Revenue 1Y (TTM)37.64%
Revenue growth 3Y124.11%
Revenue growth 5YN/A
Sales Q2Q%147.62%

3.2 Future

The Earnings Per Share is expected to grow by 2.21% on average over the next years.
The Revenue is expected to grow by 33.41% on average over the next years. This is a very strong growth
EPS Next Y-2.93%
EPS Next 2Y-5.23%
EPS Next 3Y2.21%
EPS Next 5YN/A
Revenue Next Year35.69%
Revenue Next 2Y33.24%
Revenue Next 3Y33.41%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
RXRX Yearly Revenue VS EstimatesRXRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
RXRX Yearly EPS VS EstimatesRXRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RXRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RXRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RXRX Price Earnings VS Forward Price EarningsRXRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RXRX Per share dataRXRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.23%
EPS Next 3Y2.21%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RXRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RECURSION PHARMACEUTICALS-A

NASDAQ:RXRX (2/12/2025, 8:00:01 PM)

Premarket: 8.04 -0.3 (-3.6%)

8.34

+0.68 (+8.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)03-04 2025-03-04/amc
Inst Owners84.55%
Inst Owner Change-26.34%
Ins Owners4.41%
Ins Owner Change5.13%
Market Cap3.26B
Analysts72.86
Price Target9.33 (11.87%)
Short Float %18.33%
Short Ratio4.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.16%
Min EPS beat(2)1.55%
Max EPS beat(2)4.76%
EPS beat(4)4
Avg EPS beat(4)6.06%
Min EPS beat(4)1.55%
Max EPS beat(4)9.68%
EPS beat(8)6
Avg EPS beat(8)1.83%
EPS beat(12)8
Avg EPS beat(12)-35.09%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-3.85%
Min Revenue beat(2)-14.32%
Max Revenue beat(2)6.62%
Revenue beat(4)2
Avg Revenue beat(4)-12.08%
Min Revenue beat(4)-47.54%
Max Revenue beat(4)6.91%
Revenue beat(8)2
Avg Revenue beat(8)-17.4%
Revenue beat(12)4
Avg Revenue beat(12)-13.99%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.25%
PT rev (3m)-9.86%
EPS NQ rev (1m)-16.04%
EPS NQ rev (3m)1.89%
EPS NY rev (1m)0.18%
EPS NY rev (3m)-0.03%
Revenue NQ rev (1m)4.8%
Revenue NQ rev (3m)4.8%
Revenue NY rev (1m)1.07%
Revenue NY rev (3m)7.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 49.99
P/FCF N/A
P/OCF N/A
P/B 6.21
P/tB 7.43
EV/EBITDA N/A
EPS(TTM)-1.55
EYN/A
EPS(NY)-1.74
Fwd EYN/A
FCF(TTM)-0.85
FCFYN/A
OCF(TTM)-0.81
OCFYN/A
SpS0.17
BVpS1.34
TBVpS1.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -52%
ROE -72.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 35.07%
FCFM N/A
ROA(3y)-38.3%
ROA(5y)-41.01%
ROE(3y)-51.48%
ROE(5y)-54.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 46.51%
Cap/Sales 22.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.35
Quick Ratio 4.35
Altman-Z 6.18
F-Score3
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)279.13%
Cap/Depr(5y)215.83%
Cap/Sales(3y)170.27%
Cap/Sales(5y)165.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.93%
EPS Next Y-2.93%
EPS Next 2Y-5.23%
EPS Next 3Y2.21%
EPS Next 5YN/A
Revenue 1Y (TTM)37.64%
Revenue growth 3Y124.11%
Revenue growth 5YN/A
Sales Q2Q%147.62%
Revenue Next Year35.69%
Revenue Next 2Y33.24%
Revenue Next 3Y33.41%
Revenue Next 5YN/A
EBIT growth 1Y-26.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-17.17%
EBIT Next 3Y-13.27%
EBIT Next 5YN/A
FCF growth 1Y-148.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-218.05%
OCF growth 3YN/A
OCF growth 5YN/A